Treatment-Continuity of ADHD Compared Using Immediate-Release and Extended-Release MPH

J Gordon Millichap

doi:10.15844/pedneurbriefs-19-7-5

Treatment-Continuity of ADHD Compared Using Immediate-Release and Extended-Release MPH

Pediatric Neurology Briefs

Volume 19 (2005): Issue 7

By: J Gordon Millichap

Open Access

|Jul 2005

Abstract

The continuity of methylphenidate (MPH) therapy for ADHD in young Medicaid beneficiaries (ages 6 to 17 years) treated with immediate-release (IR) or extended-release (ER) MPH formulations was compared in an analysis of statewide California Medicaid claims (2000-2003) conducted at Columbia University, New York; University of Pennsylvania, Philadelphia; and McNeil Pharmaceuticals, Fort Washington, PA.

References

Marcus SC Wan GJ Kemner JE Olfson M Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder Arch Pediatr Adolesc Med 2005 June 159 6 572 578 10.1001/archpedi.159.6.572 15939858
Open DOI Search in Google Scholar Back to article
Brown RT Amler RW Freeman WS Perrin JM Stein MT Feldman HM Treatment of attention-deficit/hyperactivity disorder: overview of the evidence Pediatrics 2005 June 115 6 e749 e757 10.1542/peds.2004-2560 15930203
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.15844/pedneurbriefs-19-7-5 | Journal eISSN: 2166-6482

Journal RSS Feed

Language: English

Page range: 52 - 52

Published on: Jul 1, 2005

Published by: Pediatric Neurology Briefs Publishers

In partnership with: Paradigm Publishing Services

Keywords:

Methylphenidate,

Immediate-Release,

Extended-Release

© 2005 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 19 (2005): Issue 7